Reversing THC-Induced Working Memory Deficits with (-)-epicatechin via KAT-II Inhibition: Targeting KYNA for Cognitive Recovery

Research and education, not medical advice.

Overview:

Adolescent exposure to THC can lead to long-term cognitive impairments by elevating kynurenic acid (KYNA) levels in the brain, particularly in the prefrontal cortex. KYNA impairs working memory by antagonizing NMDA and α7-nicotinic acetylcholine receptors, disrupting glutamatergic and cholinergic signaling. Research shows that these effects can be reversed in adulthood through KAT-II inhibition, which lowers KYNA levels. A single dose of the synthetic inhibitor PF-04859989 fully restored working memory performance in THC-exposed rats. Natural compounds like herbacetin and (-)-epicatechin also show promise as safe, reversible KAT-II inhibitors. Together, these findings highlight KAT-II inhibition as a compelling therapeutic strategy to rescue cannabinoid-induced working memory deficits.

Deep-dive:

1. What Is Kynurenic Acid (KYNA)?

Kynurenic acid (KYNA) is a neuroactive metabolite produced in the brain through the kynurenine pathway. Dietary tryptophan is broken down into kynurenine, which crosses the blood–brain barrier via LAT1 transporters. Within astrocytes, kynurenine is converted into KYNA by the enzyme kynurenine aminotransferase II (KAT-II). Unlike many brain metabolites, KYNA is not further broken down and instead accumulates in the extracellular space, where it exerts significant neuromodulatory effects.

2. Mechanisms of Cognitive Disruption

KYNA acts as a noncompetitive antagonist at the glycine site of NMDA receptors and as a competitive antagonist at α7-nicotinic acetylcholine receptors (α7-nAChRs). This dual blockade interferes with glutamatergic and cholinergic signaling, two pathways essential for synaptic plasticity, working memory, and cognitive flexibility. At NMDA receptors, KYNA dampens long-term potentiation (LTP)—a cellular mechanism underlying learning and memory (Hilmas et al., 2001; Wu et al., 2007). Meanwhile, α7-nAChR antagonism suppresses the release of glutamate and dopamine in the prefrontal cortex, impairing attention and executive function (Albuquerque & Schwarcz, 2013; Konradsson-Geuken et al., 2010). Elevated KYNA has been linked to age-related memory decline and drug-induced cognitive impairment, and reducing its levels has been shown to restore performance in both working memory and object recognition tasks (Parsons et al., 2014; Salvatore et al., 2022).

3. THC Exposure and Working Memory Recovery

A pivotal study by Salvatore et al. (2022) demonstrated the causal role of KYNA in cognitive dysfunction following adolescent THC exposure. Rats exposed to low-dose THC vapor during adolescence developed persistently elevated KYNA and KAT-II upregulation in the prefrontal cortex—a region crucial for memory. In adulthood, these rats showed significant working memory deficits, even without continued THC exposure. However, a single dose of PF-04859989, a selective KAT-II inhibitor, rapidly reduced KYNA levels and fully restored working memory to control levels. This indicates that KAT-II inhibition in adulthood can reverse long-lasting, KYNA-driven impairments in prefrontal glutamatergic signaling caused by earlier cannabinoid exposure.

4. Age-Related Cognitive Decline and KAT-II Inhibition

Similarly, a study by Parsons et al. (2014) found that aged rhesus monkeys with elevated KYNA levels in the prefrontal cortex displayed significant working memory impairment. Acute administration of PF-04859989 lowered cortical KYNA and robustly improved memory performance, nearly restoring it to youthful levels—without disrupting baseline neurochemistry. These findings suggest that KAT-II inhibition has potential applications in age-related cognitive decline and other KYNA-associated dysfunctions.

5. Natural KAT-II Inhibitors: Herbacetin and (-)-Epicatechin

Beyond synthetic inhibitors, Rebai et al. (2025) identified two natural flavonoids—herbacetin and (-)-epicatechin—as potent, reversible KAT-II inhibitors with favorable safety profiles. Computational modeling showed that both compounds bound with high affinity to the KAT-II active site, with docking scores of –8.66 kcal/mol (herbacetin) and –8.16 kcal/mol (epicatechin), outperforming the synthetic comparator PF‑04859989 (–7.12 kcal/mol). Enzyme assays confirmed competitive inhibition, with IC₅₀ values of 5.98 µM for herbacetin and 8.76 µM for (-)-epicatechin. Critically, both flavonoids exhibited no hepatotoxicity, cytotoxicity, or mutagenicity at concentrations up to 100 µM and were classified as low-risk compounds (toxicity classes 5 and 6), whereas PF-04859989 fell into a less favorable class 4.

6. Therapeutic Implications

Altogether, this body of evidence positions KAT-II inhibition—via both synthetic agents like PF-04859989 and natural compounds like herbacetin and (-)-epicatechin—as a promising therapeutic approach to enhance cognition, particularly working memory, by reducing excess KYNA and restoring glutamate and acetylcholine signaling in key brain regions like the prefrontal cortex, hippocampus, and striatum.

1.Hilmas C, et al. (2001).

The brain metabolite KYNA inhibits α7 nicotinic receptor activity and presynaptic glutamate release. Journal of Neuroscience. \[PMID: 11459941\] 2. Wu H-Q, et al. (2007). Blockade of NMDA glycine site by kynurenic acid contributes to cognitive dysfunction. Neuropharmacology. \[PMID: 17125742\] 3. Albuquerque EX, Schwarcz R. (2013). Kynurenic acid as a negative modulator of α7 nicotinic receptor function. Biochemical Pharmacology. \[PMID: 23648594\] 4. Konradsson-Geuken A, et al. (2010). Relevance of α7 nicotinic receptors and kynurenic acid in cognitive processes. Biological Psychiatry. \[PMID: 20159500\] 5. Parsons CG, Stöffler A, Danysz W. (2014). Kynurenine pathway modulation as a mechanism for cognitive enhancement in aged rhesus monkeys. Neuropharmacology, 85:163–169. https://pubmed.ncbi.nlm.nih.gov/24607894 6. Salvatore MF, Johnson LA, Madden AM, Duangdao DML, Zhu G, Schwarcz R. (2022). Kynurenic acid and cognitive deficits after adolescent exposure to THC vapor: Reversal by KAT II inhibition. Neuropharmacology, 110209. https://pubmed.ncbi.nlm.nih.gov/36483135 7. Rebai R, Jasmin L, Boudah A. (2025). Identification of Two Flavonoids as New and Safe Inhibitors of Kynurenine Aminotransferase II via Computational and In Vitro Study. Pharmaceuticals. \[PMID: 39861140\]

Schematic representation of the kynurenine pathway of tryptophan degradation. Kynurenic acid \(KYNA\) is synthesized from kynurenine by kynurenine aminotransferases \(KATs\). In the second ramification of the kynurenine pathway, kynurenine is metabolized by kynurenine 3-monooxygenase \(KMO\), leading to NAD+ as final product. For a complete representation of the pathway, see Schwarcz et al. \(22\).

Basal extracellular kynurenic acid \(KYNA; panel A\) and glutamate \(panel B\) levels in the medial prefrontal cortex of adult \[post-natal day \(PND\) 75\] male rats chronically exposed to delta 9-tetrahydrocannabinol \(THC\) or its vehicle \(cremophor and saline 1:1:18; Vehicle\) during the adolescent period. Ascending doses of THC or its vehicle were administered by i.p. to adolescent rats, from PD 35 to PD 45, wh. Data are the mean ± standard error of the mean \(SEM\); n = 5/6 male rats/group. **p < 0.01 significantly different from the respective vehicle group based on Student’s t-test.

Extracellular kynurenic acid \(KYNA; panel A,B\) and glutamate \(panel C,D\) levels in the medial prefrontal cortex of adult \[post-natal day \(PND\) 75\] male rats chronically exposed to delta 9-tetrahydrocannabinol \(THC\) or its vehicle \(cremophor and saline 1:1:18; vehicle\). Ascending doses of THC or its vehicle were administered by i.p. to adolescent rats, from PD 35 to PD 45. \(A,C\) Data mean ± standard error of the mean \(SEM\) are expressed as a percentage of the averaged three baseline values prior to treatment. \(B,D\) Bar graphs of the areas under the curves \(AUC\), calculated as the percentage of changes in basal values over time. Data were analyzed by three-way \(A,C\) or two-way \(B,D\) ANOVA and subsequent Tukey’s post hoc test for multiple comparisons. \(A\) p < 0.05, **p < 0.01, p < 0.001 Vehicle KYN vs Vehicle-Saline and THC-Saline; #p < 0.05, ##p < 0.01 THC-KYN vs Vehicle-Saline and THC-Salina; \(B\) p < 0.001 Vehicle-KYN vs Vehicle-Saline and THC-Saline;** p < 0.01 THC-KYN vs Vehicle-Saline and THC-Saline. \(C\) p < 0.05 Vehicle-Saline vs Vehicle-KYN and THC-Saline; n = 5/6 male rats/group.

Copyright © 2022 Beggiato, Ieraci, Zuccarini, Di Iorio, Schwarcz and Ferraro.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Archived into the Nootopics wiki from r/NooTopics — originally posted by u/makefriends420 on 2026-02-13. Curated, not authored by the community.